

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Brilliant Violet 785(TM) anti-human CD28

RRID:AB_2632607

Type: Antibody

Proper Citation

BioLegend Cat# 302950, RRID:AB_2632607

Antibody Information

URL: http://antibodyregistry.org/AB_2632607

Proper Citation: BioLegend Cat# 302950, RRID:AB_2632607

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD28

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_2632607

Vendor: BioLegend

Catalog Number: 302950

Alternative Catalog Numbers: 302949

Record Creation Time: 20250820T050703+0000

Record Last Update: 20250820T205032+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD28.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Karaliota S, et al. (2025) Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques. iScience, 28(4), 112232.

de Armas LR, et al. (2024) Accelerated CD8+ T cell maturation in infants with perinatal HIV infection. iScience, 27(5), 109720.

Pandit H, et al. (2023) Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes. iScience, 26(2), 105929.

Bergamaschi L, et al. (2021) Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity, 54(6), 1257.

Rha MS, et al. (2021) PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19. Immunity, 54(1), 44.